ImmunityBio, Inc. IBRX Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s common stock, shares authorized (in shares)?
- ImmunityBio, Inc. (IBRX) reported common stock, shares authorized (in shares) of $1.65B in Q1 2026.
- How has ImmunityBio, Inc.'s common stock, shares authorized (in shares) changed year-over-year?
- ImmunityBio, Inc.'s common stock, shares authorized (in shares) increased by 22.2% year-over-year, from $1.35B to $1.65B.
- What is the long-term trend for ImmunityBio, Inc.'s common stock, shares authorized (in shares)?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s common stock, shares authorized (in shares) has grown at a 27.0% compound annual growth rate (CAGR), from $500M to $1.65B.